Harmony Biosciences Files 8-K: Director/Officer Changes & Compensation

Ticker: HRMY · Form: 8-K · Filed: Apr 3, 2025 · CIK: 1802665

Harmony Biosciences Holdings, INC. 8-K Filing Summary
FieldDetail
CompanyHarmony Biosciences Holdings, INC. (HRMY)
Form Type8-K
Filed DateApr 3, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, disclosure, officer-changes

TL;DR

Harmony Biosciences 8-K: Leadership changes and comp details filed April 3rd.

AI Summary

Harmony Biosciences Holdings, Inc. filed an 8-K on April 3, 2025, reporting changes in directors and officers, and compensatory arrangements. The filing also includes information related to Regulation FD and financial statements/exhibits. The company is incorporated in Delaware and its principal executive offices are located in Plymouth Meeting, PA.

Why It Matters

This filing indicates potential shifts in the company's leadership and executive compensation structure, which could impact strategic direction and investor confidence.

Risk Assessment

Risk Level: low — This is a routine filing reporting standard corporate governance and disclosure items.

Key Players & Entities

FAQ

What specific items are being reported under Item Information?

The filing reports on the Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Regulation FD Disclosure; and Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported was on April 2, 2025.

What is the company's Standard Industrial Classification code?

The SIC code is 2834, Pharmaceutical Preparations.

What is the company's fiscal year end?

The fiscal year end is December 31st.

What is the SEC file number for Harmony Biosciences Holdings, Inc.?

The SEC file number is 001-39450.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 3, 2025 regarding Harmony Biosciences Holdings, Inc. (HRMY).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing